摘要
目的对人尿激肽原酶滴注治疗心源性脑栓塞患者的疗效进行研究和判定。方法方便选取该院2013年2月—2014年1月收治的60例心源性脑栓塞患者进行随机分组为对照组与观察组,各30例,对照组给予阿托伐他汀钙及氯吡格雷进行治疗,观察组则在对照组的基础上给予患者人尿激肽原酶治疗,并观察2组心源性脑栓塞患者治疗前后的Rankin评分、NIHSS评分,临床疗效及不良反应发生概率。结果观察组心源性脑栓塞患者的Rankin评分、NIHSS评分分别为(7.65±3.62)分及(1.53±0.81)分均优于对照组,P<0.05,同时总好转概率为80.00%优于对照组,其不良反应发生概率比较差异无统计学意义。结论给予心源性脑栓塞患者人尿激肽原酶进行治疗的效果显著。
Objective To the urine in the treatment of cardiac shock peptide enzyme drip study and judge the curative effect of cerebral embolism patients. Methods Convenient selection from February 2013 to January 2014, 60 cases with cardiac cerebral embolism patients randomized to the control group and observation group, each 30 cases, control group given atorvastatin calcium and clopidogrel treatment, observation group in the control group on the basis of giving human urine excitation peptide enzyme treatment, patients and observe cardiac cerebral embolism patients of two groups before and after treatment of Rankin scale, NIHSS score, clinical curative effect and adverse reaction probability. Results The observation group of patients with cardiac cerebral embolism Rankin scale, NIHSS score respectively(7.65±3.62) points and(1.53±0.81)points were superior to control group, P < 0.05, at the same time improved total probability is 80.00% better than the control group, the adverse reaction probability there was no significant difference. Conclusion Cardiac cerebral embolism patients' human urine excitation peptide enzyme for treatment of sister-in-law significantly.
出处
《中外医疗》
2016年第29期146-148,共3页
China & Foreign Medical Treatment
关键词
心源性脑栓塞
临床疗效
人尿激肽原酶
神经功能
Cardiac cerebral embolism
Clinical curative effect
Urine excitation peptide enzyme
Nerve function
